Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming ...
MIT researchers have dramatically lowered the error rate of prime editing, a technique with promise for treating numerous ...
The report provides a comprehensive analysis of the genome editing market, focusing on technologies like CRISPR-Cas, TALEN, ...
As CRISPR continues to drive breakthroughs in medicine, agriculture, and synthetic biology, understanding its origins does more than tell an ancient story. It provides a blueprint for engineering the ...
Natural systems such as CRISPR-associated transposons (CASTs) offer a targetable, one-step way to edit genomes. However, ...
Cas9, genome editing has been revolutionized by the ability to introduce targeted genetic changes with unprecedented ...
New enhancer protein expands IDT's market-leading portfolio of HDR reagents, empowering cell and gene therapy developers to ...
CRISPR-Cas systems are adaptive immune systems found in prokaryotes that defend against invading nucleic acids through CRISPR ...
The new prime editors are about as efficient as their predecessors but make up to 60-fold fewer ‘indel’ mistakes.
A research team led by Prof. Wang Yanli from the Institute of Biophysics of the Chinese Academy of Sciences has revealed the ...
A screening approach has been designed to measure efficiency and specificity for thousands of CRISPR-associated transposons ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback